Clinical Trial Update: A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM） [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating a rapamycin-eluting intracranial stent for symptomatic intracranial atherosclerotic disease; the study is currently not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracranial Atherosclerotic Disease

Drugs mentioned

• Rapamycin Target Eluting Stent (sirolimus)

Snippet

Sponsor: MicroPort NeuroTech Co., Ltd. | Conditions: Intracranial Arteriosclerosis | Phase 3 | Status: NOT_YET_RECRUITING